Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects several systems in the body, including movement, balance, and autonomic functions. It is often confused with Parkinson’s disease due to similar symptoms but is a distinct condition with broader systemic impact.
MSA symptoms vary widely and may appear in different combinations. Common signs include loss of balance and coordination (ataxia), severe drops in blood pressure when standing (orthostatic hypotension), bladder dysfunction (retention or incontinence), constipation, erectile dysfunction, speech and swallowing difficulties, sleep disturbances, breathing problems, and Parkinson-like symptoms such as rigidity and tremor.
MSA is often described as a combination of three overlapping conditions:
- Cerebellar ataxia (affecting coordination and balance)
- Atypical parkinsonism (movement-related symptoms similar to Parkinson’s disease)
- Autonomic dysfunction (also known as dysautonomia, affecting involuntary body processes)
Historically, these symptoms were classified as separate disorders:
- Olivopontocerebellar Atrophy (OPCA)
- Striatonigral Degeneration (SND)
- Shy-Drager Syndrome (SDS)
Today, medical consensus recognizes two main types of MSA:
- MSA-C (cerebellar type), where coordination and balance issues are the earliest symptoms
- MSA-P (parkinsonian type), where movement symptoms similar to Parkinson’s disease appear first
Autonomic dysfunction is now considered a core feature of both types, rather than a separate category.
The exact cause of Multiple System Atrophy remains unknown. It is not considered a hereditary disease and typically occurs sporadically, without a family history. MSA affects both men and women, most commonly beginning around the age of 50. The average disease progression spans approximately 10 years.
Although there is currently no cure for MSA, early diagnosis and comprehensive medical care can help manage symptoms, improve quality of life, and potentially extend survival.